Zilker T, Bottermann P
Med Klin. 1978 Feb 17;73(7):250-3.
Intravenous glucose tolerance tests were performed in 17 patients suffering from hyperthyreosis before and after a week of treatment with propranolol. The blood taken until the 125. minute after the glucose load was used for the determination of serum glucose, the free fatty acids (FFA), the free glycerol and the radioimmunologically measurable insulin (IRI). The following results were received: After the treatment with propranolol the glucose tolerance decreased significantly. The insulin secretion was diminished showing a significant difference for the fifth minute after glucose injection. The concentration of the FFA remained unchanged. The levels of the free glycerol were significantly lower after the propranolol treatment than before. Though an inhibition of lipolysis was possible by the propranolol treatment the glucose tolerance did not improve due to the inhibition of insulin secretion under propranolol. Beta-adrenergic blocking agents do not lead to an essential change in the carbohydrate- and lipometobolism. Therefore, their use in hyperthyroidism is mainly justified because of the cardial symptomatology.
对17例甲状腺功能亢进患者在使用普萘洛尔治疗一周前后进行了静脉葡萄糖耐量试验。在葡萄糖负荷后125分钟内采集的血液用于测定血清葡萄糖、游离脂肪酸(FFA)、游离甘油和放射免疫法可测定的胰岛素(IRI)。得到以下结果:使用普萘洛尔治疗后,葡萄糖耐量显著降低。胰岛素分泌减少,在注射葡萄糖后第5分钟显示出显著差异。FFA浓度保持不变。普萘洛尔治疗后游离甘油水平明显低于治疗前。虽然普萘洛尔治疗可能抑制脂肪分解,但由于普萘洛尔抑制胰岛素分泌,葡萄糖耐量并未改善。β-肾上腺素能阻滞剂不会导致碳水化合物和脂质代谢的本质变化。因此,它们在甲状腺功能亢进症中的应用主要是因为心脏症状而合理的。